Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab

被引:15
作者
Navarro-Perea, Carmen [1 ]
Garcia-Gonzalez, Javier [2 ]
Perez-Blazquez, Eugenio [1 ]
机构
[1] Hosp Madrid, Dept Ophthalmol, Madrid, Spain
[2] Hosp Madrid, Dept Rheumatol, Madrid, Spain
关键词
CTLA-4; melanoma; papillitis; PD-1; pembrolizumab; uveitis; INHIBITORS; SAFETY;
D O I
10.4103/ijo.IJO_1161_19
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Pembrolizumab is a programmed cell death protein 1 (PD-1) monoclonal antibody used in the treatment of metastatic melanomas. Severe ocular complications appear in less than 1% of the patients and require early treatment. We present the case of a patient diagnosed with a BRAF mutated metastatic melanoma. Ocular pain and a blurred vision appeared after treatment and the patient visited the ophthalmology emergency room, where he was diagnosed with acute anterior uveitis (AAU), synechiae, and bilateral papillitis. The patient was treated with topical corticosteroids, prednisone, and mydriatics, which immediately improved the patient's status. Therefore, when an ocular inflammatory disease exists, immune checkpoint inhibitor treatments must be ruled out as possible causes.
引用
收藏
页码:2075 / 2077
页数:3
相关论文
共 6 条
[1]  
Aaberg Michael T, 2017, Retin Cases Brief Rep, V11, P348, DOI 10.1097/ICB.0000000000000368
[2]   A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab [J].
Abu Samra, Khawla ;
Valdes-Navarro, Manuel ;
Lee, Stacey ;
Swan, Robert ;
Foster, C. Stephen ;
Anesi, Stephen D. .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2016, 26 (03) :E46-E48
[3]  
Davies M, 2017, IMMUNOTARGETS THER, V6, P51, DOI 10.2147/ITT.S141577
[4]   Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma [J].
Ivashko, Igor N. ;
Kolesar, Jill M. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (04) :193-201
[5]  
Kirollos SH, 2016, PHARMACOTHERAPY, V36, P183
[6]   Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma [J].
Pollack, M. H. ;
Betof, A. ;
Dearden, H. ;
Rapazzo, K. ;
Valentine, I. ;
Brohl, A. S. ;
Ancell, K. K. ;
Long, G. V. ;
Menzies, A. M. ;
Eroglu, Z. ;
Johnson, D. B. ;
Shoushtari, A. N. .
ANNALS OF ONCOLOGY, 2018, 29 (01) :250-255